Table 1.
The screening using orexin/YC2.1 transgenic mice
|
Substances |
Concentration |
n |
Response |
|---|---|---|---|
| Peptides | |||
| Neuropeptide Y | 100 nm | 20 | ND |
| Orexin A | 1 μm | 27 | ND |
| Galanin | 1 μm | 17 | ND |
| QRFP | 300 nm | 13 | ND |
| Melanin-concentrating hormone | 1 μm | 10 | ND |
| Galanin-like peptide | 100 nm | 20 | ND |
| Neurotensin | 100 nm | 8 | Activation |
| Calcitonin gene-related peptide | 100 nm | 8 | ND |
| Insulin | 300 nm | 11 | ND |
| Urocortin | 300 nm | 21 | ND |
| Cocaine-and amphetamine-regulated transcript | 300 nm | 18 | ND |
| CCK-8S | 10 nm | 20 | Activation |
| α-Melanocyte-stimulating hormone | 1 μm | 13 | ND |
| Agouti-related protein | 1 μm | 19 | ND |
| Neuropeptide B | 1 μm | 25 | ND |
| Substance P | 300 nm | 16 | ND |
| Neuropeptide S | 1 μm | 10 | ND |
| Prolactin-releasing peptide | 1 μm | 13 | ND |
| Vasoactive intestinal peptide | 1 μm | 17 | ND |
| Vasopressin | 300 nm | 13 | Activation |
| Oxytocin | 300 nm | 13 | Activation |
| Nonpeptides | |||
| Serotonin | 100 μm | 13 | Inhibition |
| Noradrenaline | 100 μm | 10 | Inhibition |
| Dopamine | 100 μm | 15 | Inhibition |
| Muscimol | 30 μm | 13 | Inhibition |
| Adenosine | 100 μm | 17 | ND |
| Histamine |
100 μm
|
17 |
ND |
All substances were applied by bath application for 2 min. ND, Not detected.